Gait & Posture – January 2018
A “HOLTER” for Parkinson’s disease: Validation of the ability to detect on-off states using the REMPARK system
Àngels Bayés, Albert Samà, Anna Prats, Carlos Pérez-López, Maricruz Crespo-Maravera, Juan Manuel Moreno, Sheila Alcaine, Alejandro Rodriguez-Molinerod, Berta Mestre, Paola Quispe, Ana Correia de Barros, Rui Castro, Alberto Costa, Roberta Annicchiarico, Patrick Browne, Tim Counihan, Hadas Lewy, Gabriel Vainstein, Leo R. Quinlan, Dean Sweeney, Gearóid ÓLaighin, Jordi Rovira, Daniel Rodriguez-Martin, Joan Cabestany, “A “HOLTER” for Parkinson’s disease: Validation of the ability to detect on-off states using the REMPARK system”, Gait & Posture, Vol. 59, pp. 1-6, January 2018, DOI: 10.1016/j.gaitpost.2017.09.031
The treatment of Parkinson’s disease (PD) with levodopa is very effective. However, over time, motor complications (MCs) appear, restricting the patient from leading a normal life. One of the most disabling MCs is ON-OFF fluctuations. Gathering accurate information about the clinical status of the patient is essential for planning treatment and assessing its effect. Systems such as the REMPARK system, capable of accurately and reliably monitoring ON-OFF fluctuations, are of great interest.
To analyze the ability of the REMPARK System to detect ON-OFF fluctuations.
Forty-one patients with moderate to severe idiopathic PD were recruited according to the UK Parkinson’s Disease Society Brain Bank criteria. Patients with motor fluctuations, freezing of gait and/or dyskinesia and who were able to walk unassisted in the OFF phase, were included in the study. Patients wore the REMPARK System for 3 days and completed a diary of their motor state once every hour.
The record obtained by the REMPARK System, compared with patient-completed diaries, demonstrated 97% sensitivity in detecting OFF states and 88% specificity (i.e., accuracy in detecting ON states).
The REMPARK System detects an accurate evaluation of ON-OFF fluctuations in PD; this technology paves the way for an optimisation of the symptomatic control of PD motor symptoms as well as an accurate assessment of medication efficacy.